2型糖尿病
医学
疾病
心血管健康
路线图
动脉粥样硬化性心血管疾病
糖尿病
2型糖尿病
重症监护医学
老年学
心脏病
梅德林
替代医学
生物信息学
风险评估
临床研究
医学研究
转化研究
复杂疾病
代谢综合征
研究设计
冠心病
人类健康
成果研究
作者
E. Dale Abel,Rexford S. Ahima,Ethan J. Anderson,David D. Berg,Jeffrey S. Berger,Saumya Das,Mark W. Feinberg,Edward A. Fisher,Michael Garshick,Chiara Giannarelli,Ira J. Goldberg,Naomi M. Hamburg,Sangwon F. Kim,Filipe A. Moura,Chiadi E. Ndumele,Jonathan D Newman,Marc S. Sabatine,Elizabeth Selvin,Ravi Shah
出处
期刊:Circulation Research
[Lippincott Williams & Wilkins]
日期:2026-01-15
卷期号:138 (2): e325798-e325798
标识
DOI:10.1161/circresaha.125.325798
摘要
Despite major advances in medical therapies and prevention strategies, the risk of cardiovascular complications in patients with both type I and type II diabetes remains substantially elevated. In 2019, the American Heart Association sought applications for a Strategically Focused Research Network on Cardiometabolic Health and Type 2 Diabetes. In 2020, 4 centers were named, including Brigham and Women's Hospital, Johns Hopkins University, New York University, and the University of Iowa. These centers performed basic, translational, and clinical studies to provide insights to explain the over 2-fold risk of cardiovascular complications in diabetes. Clinical studies and studies in cells and animals aimed to uncover new mechanisms responsible for disease development. Studies using human populations sought to uncover new biomarkers to prognosticate risk. In this review, we discuss several key issues and current and developing methods to understand why diabetes drives atherosclerotic cardiovascular disease and heart failure. Both human data and experimental models are considered. We integrate a review of these topics with work from the Strategically Focused Research Network and conclude with suggestions for identifying novel risk factors and future experimental research.
科研通智能强力驱动
Strongly Powered by AbleSci AI